GSK plc DRC (GSK)

GSK plc DRC is a depositary receipt listed on the NYSE that represents ordinary shares of GSK plc, a healthcare company focused on pharmaceuticals. The underlying business researches, develops, and manufactures vaccines, specialty medicines, and general medicines used to help prevent and treat disease in the UK, the US, and other international markets. Its operations are organized into Commercial Operations and Total R&D. GSK’s portfolio includes specialty medicines in areas such as oncology, respiratory and immunology, inflammation, HIV, and certain rare or difficult-to-treat conditions, alongside vaccines covering a broad range of infectious diseases. The company also supplies general medicines for respiratory, bacterial, and other common therapeutic areas. GSK has collaborations with CureVac on mRNA vaccine development and with AN2 Therapeutics on tuberculosis therapies. Formerly known as GlaxoSmithKline plc, the company adopted the name GSK plc in May 2022 and is headquartered in London, United Kingdom.

Jump between the core stock analysis sections, valuation data, fair value models, technical outlook, and FAQ.